BioSpace News Archive

Reported net sales of $874.3 million, down 7.6% in the first quarter. Organic sales declined 4.3% Reported operating loss was $124.8 million and operating margin was negative 14.3%. Non-GAAP operating income was $130.7 million and operating income margin was 14.9% Reported EPS was a loss of $0.63. Non-GAAP EPS was $0.43 Available liquidity of ~ $1.3 billion CHARLOTTE, N.C., May 08, 2020 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), The Dental Solutio

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in the interest of the health and safety of its shareholders, directors, officers, employees and meeting attendees in light of the current COVID-19 pandemic and the declared state of emergency in New Jersey, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Merck’s 2020 Annual Meeting will b

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will present at the BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 8:20 a.m. ET. The conference will be held in a virtual meeting format. Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat. The event will

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the first quarter ended March 31, 2020. “Our team remains focused on progressing our programs as we navigate the evolving business and regulatory environment,” said George Lasezkay, Pharm.D., J.D., Presiden

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2020. First Quarter 2020 and Recent Operating Highlights Revenue of $8.3 million for the first quarter of 2020; E-commerce sales to 24% of total net revenue, up from 15% for the first quarter of 2019; Launched upd

The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. -- All six analyzed moderate-to-severe COVID-19 patients treated with opaganib under compassionate use in Israel were weaned from oxygen and discharged from the hospital -- Opaganib’s unique mechanism of action has both anti-inflammatory and anti-viral activities, targeting a critical host factor, minimizing potential development of resistance du

Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today reported first quarter 2020 financial results along with a general business update. “We reached a significant milestone in our Phase 3 trial with OCU300 for ocular Graft vs. Host Disease (oGVHD) with the completion of our planned enrollment. We expect topline results by the end of this

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), will report financial results for the third quarter of fiscal year

Virtual oral presentation will include updated efficacy and safety data from pivotal Phase 2 KarMMa study of ide-cel- -Biologics License Application under review with U.S. Food and Drug Administration (FDA)- CAMBRIDGE, Mass.--( BUSINESS WIRE )-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that updated results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of idecabtagene vicleucel (ide-cel; bb2121), an invest

HOUSTON, May 08, 2020 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 15, 2020 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2020 and to provide a business overview. To access the live confe